Novo Nordisk (NVO) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares of this drugmaker have returned -10.2% over the past month versus the Zacks S&P 500 composite's +1.5% change. The Zacks Large Cap Pharmaceuticals industry, to which Novo Nordisk belongs, has gained 4.4% over this period. Now the key question is: Where could the stock be headed in the near term?
Головну думку ми показуємо публічно. Створіть безкоштовний акаунт, щоб читати повну статтю, зберігати її, обговорювати та поєднувати з ринковим і OSINT-контекстом.